Navigation Links
Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
Date:2/25/2011

ated expenses.  The lower costs also resulted from higher prior year expenses associated with preparation for the June 2009 FDA Advisory Committee meeting for KRYSTEXXA, coupled with the wind down of the open label extension clinical trial for KRYSTEXXA.  

Selling, general and administrative expenses decreased $5.8 million, or 19%, to $25.0 million for the year ended December 31, 2010, from $30.8 million for the year ended December 31, 2009.  The decrease was partially due to lower marketing costs, which included $2.1 million of lower expenses associated with the preparation for a possible commercial launch of KRYSTEXXA in 2009 and a decrease of $2.3 million in compensation related and severance expenses.

Other expense, net increased $5.2 million, or 43%, to $17.3 million for the year ended December 31, 2010 as compared to $12.1 million for the year ended December 31, 2009, primarily due to the variance in non-cash mark-to-market valuation adjustments to the Company's warrant liability in 2010 versus the prior year.

Conference CallSavient's management team will host a live conference call and webcast on Friday, February 25, 2011 at 9:00 a.m. Eastern Time to review the fourth quarter and year-end 2010 financial results.  To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International).  The conference identification number is 45733606.  The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com.  Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.

A telephone replay will be available from 12:00 p.m. Eastern Time on February 25, 2011 through 11:59 p.m. Eastern Time on March 11, 2011 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
2. Savient Closes Sale of $230 Million in Convertible Senior Notes
3. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
4. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
5. Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer
6. Savient Pharmaceuticals Announces Search for CEO
7. Savient Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Savient Pharmaceuticals Announces Expected Availability of KRYSTEXXA™ for Prescription and Reports Third Quarter 2010 Financial Results
9. Savient Pharmaceuticals to Hold Third Quarter 2010 Financial Results Conference Call on Friday, November 5, 2010
10. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
11. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... BERGEN, Norway , September 23, 2014 /PRNewswire/ ... "Company"), an oncology biopharmaceutical company, today announces it ... million) Seeding Drug Discovery Award from the UK,s ... against BGB002, its proprietary, novel cancer target. ... are to identify and fund especially promising, innovative ...
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... , Sept. 23, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... additions to its Scientific Advisory Board.  The new members ... Davies , PhD. Dr. Acker is a ...
Breaking Medicine Technology:BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 2BerGenBio Granted a Prestigious Wellcome Trust Seeding Drug Discovery Award 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7
... Harco Metal Products (Harco), an industry leader in tube fabrication, systems ... manufacture MediGLIDER™ products for ConMediSys. , ... ConMediSys, the developer of safety products for health ... cost associated with staff injuries caused by physically lifting and moving ...
... 23 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... 26, 2010 , at 8:00 a.m. Eastern Time ( 5:00 ... , , ... live webcast of the presentation on the company,s website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar ...
Cached Medicine Technology:Harco Partners With ConMediSys to Deliver Patient Safety and Equipment Integrity 2Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide a Clinical Update on Carfilzomib 2
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
(Date:9/23/2014)... Wellesley, Mass., September 23, 2014 – BCC Research ( ... Joint Reconstruction and Replacement: Materials, Technologies, and Global Markets ... is expected to increase to nearly $16.2 billion by ... 4.2% from 2013 through 2018. The U.S. occupies the ... CAGR of 5.1%. , Revision and partial joint replacement ...
(Date:9/23/2014)... eCaring, a leading health care quality ... contract to provide its unique Web-based home health care ... New York City’s largest not-for-profit health plans. Elderplan, an ... to help enhance the care of its Medicare, Medicaid ... Elderplan has been at the forefront of offering New ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... revenue for the Fruit and Vegetable Markets ... consumption and fruit prices benefited operators over the ... industry follow unique preference and demographic trends, including ... US population. While per capita fruit and vegetable ...
(Date:9/23/2014)... the results of their cancer research at ESMO ... Joint Symposium: ESMO-ASCO: The Evolution of the ... AM - 12:30 PM, Room: Granada, Abstract 121IN: ... new forms of cancer clinical research? The example ... Paper session: Melanoma and other skin tumors , ...
Breaking Medicine News(10 mins):Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 2Health News:Global Market for Joint Reconstruction and Replacement to reach $16.2 Billion in 2018; The U.S. Market Moving at 5.1% CAGR 3Health News:eCaring Signs Care Management Contract with Elderplan, Inc. 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3
... new study has established the wholesomeness of whole wheat ... breast cancer risk in the offspring.// ,Dr ... her colleagues examined the benefits of dietary changes on ... health. These results could well mimic the occurrence in ...
... health care for patients that was released by the ... countries, except the U.S. ,In the survey ... was found that Canada lagged in several aspects including ... doctors availability after hours, multi-discipline teams for treatment of ...
... to arouse strong feelings either way has been brought up ... the proposal suggests mercy killing of// new borns who are ... Gynaecology put forth this recommendation as the solution to the ... are being kept alive because of the advanced technology ...
... 7 and the theme selected is Cancer and Women. ... on that day// to promote awareness and motivate people ... ,"Run 4 Cancer" will be flagged off by SSP ... Allahabad Division RN Tripathi will preside over a lecture ...
... a biotechnology firm based in Seattle has called off further ... year following the untimely deaths// of few of the patients ... efficacy of the cancer drug Xyotax. ,The CEO of ... the volunteer s who were cancer patients do not seem ...
... raising the retirement age for civil servants from 60 to ... soaring pension bill//. ,Moreover, improving health standards and ... retiring are being cited among the reasons for the move. ... Reforms (NCGR) told The News International that the reform body ...
Cached Medicine News:Health News:Consider Euthanasia For Severely Disabled Babies, College Tells Doctors 2Health News:Awareness about Women's Cancers- A National Concern 2Health News:Multiple deaths forces cancer trial to be called off 2Health News:Pakistan civil servants may retire at 62 2
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Inquire...
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
... offer a safe alternative to using positive ... applications such as PCR(a), pipetting radioactive materials ... are excellent for tissue culture, gel loading, ... prevent aerosol contaminants and liquids from reaching ...
Medicine Products: